The company said it reported GAAP net loss per share of $4.42 and Adjusted loss per share of $0.11 for Q4 2023, and full-year 2023 EPS of $20.00 on a GAAP basis and $26.09 on an Adjusted basis.

1. 01

   The company said it reported GAAP net loss per share of $4.42 and Adjusted loss per share of $0.11 for Q4 2023, and full-year 2023 EPS of $20.00 on a GAAP basis and $26.09 on an Adjusted basis.

2. 02

   The company said its Q4 2023 results reflected a further increase in Medicare Advantage medical cost trends, driven mainly by higher-than-anticipated inpatient utilization in November and December, and a further increase in non-inpatient trends.

3. 03

   The company disclosed that its consolidated benefits expense ratio on a GAAP basis was 90.7% in Q4 2023, higher than 87.3% in Q4 2022, and that its consolidated operating cost ratio was 14.6%, lower than 15.9%.

4. 04

   The company gave its initial full-year 2024 EPS guidance of 'approximately $14.87' on a GAAP basis and 'approximately $16.00' on an Adjusted basis, and said it assumed the higher Medicare Advantage medical costs seen in Q4 2023 would persist throughout 2024.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.